Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-22T15:09:20.811Z Has data issue: false hasContentIssue false
  • English
  • Français

A clinical trial of WRL 105 strain live attenuated influenza vaccine comparing four methods of intranasal vaccination

Published online by Cambridge University Press:  15 May 2009

D. S. Freestone ,
C. H. Bowker ,
E. Letley ,
R. D. Ferris ,
W. G. White  and
G. M. Barnes
D. S. Freestone
Affiliation:
The Wellcome Research Laboratories, Beckenham, Kent
C. H. Bowker
Affiliation:
The Wellcome Research Laboratories, Beckenham, Kent
E. Letley
Affiliation:
The Wellcome Research Laboratories, Beckenham, Kent
R. D. Ferris
Affiliation:
The Wellcome Research Laboratories, Beckenham, Kent
W. G. White
Affiliation:
British Leyland UK Limited, Cowley, Oxford
G. M. Barnes
Affiliation:
British Leyland UK Limited, Cowley, Oxford
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

A single intranasal dose of 107.0 EID50 recombinant WRL 105 strain live attenuated influenza vaccine was administered intranasally to 193 volunteers either as nose drops or by one of three spray devices which produced sprays of differing physical characteristics. In volunteers with homologous haemagglutinating inhibiting antibody titres of ⋜ 20 before vaccination, seroconversion rates varied widely from 80% following the administration of drops to 71%, 57% and 28% with the three spray devices.

In the week following vaccination 16 (22%) of 74 volunteers who were found to show a fourfold or greater antibody response took analgesics to control symptoms in comparison with 4 (7%) of 58 volunteers who exhibited no sero-logical response to vaccination (P < 0.05). However, neither the occurrence of upper respiratory nor systemic symptoms were significantly different in these two groups and the degree of attenuation of the recombinant WRL 105 strain appears to be acceptable for future use.

Type
Research Article
Information
Journal of Hygiene , Volume 76 , Issue 3 , June 1976 , pp. 459 - 466
Copyright
Copyright © Cambridge University Press 1976

References

REFERENCES

Beare, A. S., Hobson, D., Reed, S. E. & Tyrrell, D. A. J. (1968). A comparison of live and killed influenza-virus vaccines. Lancet ii, 418–20.CrossRefGoogle Scholar
Beare, A. S., Habershon, R. B., Tyrrell, D. A. J. & Hall, T. S. (1973). Recombinant live influenza vaccine virus - tests of transmissibility in man. Journal of Biological Standardization 1, 233–6.CrossRefGoogle Scholar
Bears, A. S., Maassab, H. F., Tyrrell, D. A. J., Slepuskin, A. N. & Hall, T. S. (1971). A comparative study of attenuated influenza viruses. Bulletin of the World Health Organization 44, 593–8.Google Scholar
Freestone, D. S., Hamilton-Smith, S., Schild, G. C., Buckland, R., Chinn, S. & Tyrrell, D. A. J. (1972). Antibody responses and resistance to challenge in volunteers vaccinated with live (H3N2) influenza vaccines. Journal of Hygiene 70, 531–42.CrossRefGoogle ScholarPubMed
Mccahon, D. & Schild, G. C. (1972). Segregation of antigenic and biological characteristics during influenza virus recombination. Journal of General Virology 15, 73–7.CrossRefGoogle ScholarPubMed
McDonald, J. C., Zuckerman, A. J., Beare, A. S. & Tyrrell, D. A. J. (1962). Trials of live influenza vaccine in the Royal Air Force. British Medical Journal i, 1036–42.CrossRefGoogle Scholar
Morris, C. A., Freestone, D. S., Stealey, V. M. & Oliver, P. R. (1975). Recombinant WRL 105 strain live attenuated influenza vaccine. Immunogenicity, reactivity and transmissibility. Lancet ii, 196–9.CrossRefGoogle Scholar
Okuno, Y. & Nakamura, K. (1966). Prophylactic effectiveness of live influenza vaccine in 1965. Biken's Journal 9, 89–95.Google ScholarPubMed
Sever, J. L. (1962). Application of a microtechnique to viral serological investigations. Journal of Immunology 88, 320–29.CrossRefGoogle ScholarPubMed
Takatzy, G. (1955). The use of spiral loops in serological and virological micro-methods. Acta microbiologica Academiae scientiarum hungaricae 3, 191–202.Google Scholar